Arabian Journal of Chemical and Environmental Research

Vol. 13 Issue 3 (2026) 478–503

An Overview of In Silico Modeling, Simulation, and Drug Design Approaches for Protein Targets in Hypertension Management

Oruma Y. Unekwuojo

[1]*Department of Chemistry/Biochemistry, School of Technology, Federal Polytechnic Idah, Kogi State. P.M.B.1037, Nigeria*

Received 29 April 2026, Revised 11 July 2026, Accepted 15 July 2026

Cited as: *Oruma Y. Unekwuojo (2026). An Overview of In Silico Modeling, Simulation, and Drug Design Approaches for Protein Targets in Hypertension Management, Arab. J. Chem. Environ. Res. 13(3), 478-503*

Abstract

Hypertension is a major global health challenge and a leading risk factor for cardiovascular and renal diseases. Recent advances in computational drug discovery have enhanced the identification and development of novel antihypertensive agents by targeting proteins involved in blood pressure regulation. This review provides an overview of important protein targets in hypertension and discusses the application of in silico approaches, including molecular modeling, molecular docking, molecular dynamics simulations, virtual screening, pharmacophore modeling, ADMET prediction, and artificial intelligence-driven drug design. The review also highlights recent advances in computational studies, natural-product-based drug discovery, and multi-target therapeutic strategies. Although challenges related to data quality, prediction accuracy, protein flexibility, and experimental translation remain, in silico methods continue to accelerate drug discovery and support the development of safer, more effective, and cost-efficient antihypertensive therapies.

Keywords: Hypertension; Protein Targets; In Silico Drug Discovery; Molecular Docking; Molecular Dynamics Simulation; Virtual Screening; Artificial Intelligence; Computer-Aided Drug Design.

**Corresponding author.*
E-mail address: unekwuoruma@gmail.com

1. Introduction

Hypertension is a prevalent cardiovascular disorder and remains a major global health concern due to its high incidence and strong association with severe complications such as stroke, myocardial infarction, heart failure, peripheral vascular disease, and chronic kidney disease (Ahmad *et al.,* 2023). It is characterized by persistently elevated arterial blood pressure and contributes significantly to global morbidity and mortality rates. The rising prevalence of hypertension is influenced by multiple

factors, including population aging, rapid urbanization, sedentary lifestyles, unhealthy dietary habits, excessive salt intake, obesity, chronic stress, alcohol consumption, and genetic predisposition. Despite improvements in medical diagnosis and treatment strategies, long-term control of hypertension remains inadequate in many regions, particularly in low- and middle-income countries where awareness, early detection, and effective management are still limited (Rubin and Tomaszewski, 2023).

The regulation of blood pressure involves a complex and highly integrated network of physiological systems, including the renin–angiotensin–aldosterone system (RAAS), sympathetic nervous system, renal function, vascular endothelium, and ion transport mechanisms (Belinskaia *et al.,* 2024). Proper functioning of these systems is essential for maintaining cardiovascular homeostasis, while any disruption leads to increased vascular resistance, sodium and water retention, oxidative stress, inflammation, and endothelial dysfunction. These pathological changes collectively contribute to sustained elevation of blood pressure. Several important proteins play key roles in these processes, including angiotensin-converting enzyme (ACE), angiotensin II receptors, renin, aldosterone synthase, endothelial nitric oxide synthase (eNOS), endothelin receptors, and various ion channels, all of which serve as crucial therapeutic targets in antihypertensive drug development (Elgazzaz *et al.,* 2024; Yue *et al.,* 2024).

Although several classes of antihypertensive drugs are currently available, including ACE inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers, diuretics, and combination therapies, their clinical effectiveness is often limited by side effects, drug resistance, poor patient adherence, and variability in individual responses due to genetic and environmental differences (Shah *et al.,* 2024). These limitations highlight the urgent need for the discovery of novel therapeutic agents with improved efficacy, selectivity, and safety profiles. Consequently, significant research efforts are focused on identifying new protein targets and understanding their molecular interactions with potential drug candidates to improve hypertension management and therapeutic outcomes (Saric *et al.,* 2024; Gymnastiar *et al.,* 2024).

In recent years, in silico approaches have emerged as powerful and indispensable tools in modern drug discovery and development. These computational methods integrate principles from bioinformatics, computational chemistry, structural biology, and molecular pharmacology to study biological systems and predict protein–ligand interactions (Ouahabi *et al.,* 2023; Zhou *et al.,* 2024; Abbaoui *et al.,* 2025). Techniques such as molecular docking, molecular dynamics simulations, virtual screening, pharmacophore modeling, quantitative structure–activity relationship (QSAR) analysis, homology modeling, and ADMET prediction enable rapid, reliable, and cost-effective evaluation of drug candidates prior to experimental testing (Hussein *et al.,* 2024; Merimi *et al.,* 2026). This review

provides an overview of key protein targets involved in hypertension and examines the application of in silico modeling, molecular simulation, and computer-aided drug design approaches, highlighting recent advances, current challenges, and future perspectives in the field (Majumdar and Pramanik, 2024; Gayathiri *et al.,* 2024).

2. Protein Targets in Hypertension Management

Hypertension is a complex cardiovascular disorder driven by multiple interacting molecular pathways that regulate vascular tone, fluid balance, and neurohormonal signaling. The condition develops when these regulatory systems become dysregulated, leading to sustained elevation of blood pressure. Protein targets involved in these pathways are essential for understanding disease mechanisms and for designing effective therapeutic agents. These targets are broadly categorized into RAAS proteins, endothelial and vascular regulators, ion channels, and emerging molecular pathways linked to oxidative stress and inflammation.



Figure 1: Hypertension Pathophysiology and Major Protein Targets

2.1 Renin–Angiotensin–Aldosterone System (RAAS) Proteins

The renin–angiotensin–aldosterone system (RAAS) plays a central role in blood pressure regulation and electrolyte balance. Renin initiates the cascade by converting angiotensinogen to angiotensin I, making it a key rate-limiting enzyme and an important therapeutic target in hypertension (Bader and Ganten, 2023). Angiotensin-converting enzyme (ACE) converts angiotensin I into angiotensin II, a potent vasoconstrictor that increases peripheral resistance and stimulates aldosterone secretion. Angiotensin II also exerts its effects through the angiotensin II type 1 receptor (AT1R), which mediates vasoconstriction, sodium retention, and vascular remodeling (Coffman, 2024). Aldosterone

synthase regulates aldosterone production, contributing to fluid retention and elevated blood pressure through mineralocorticoid receptor activation (Kobori and Nangaku, 2024).

2.2 Endothelial and Vascular Protein Targets

Endothelial and vascular proteins play a major role in maintaining vascular homeostasis. Endothelial nitric oxide synthase (eNOS) produces nitric oxide (NO), which promotes vasodilation and reduces vascular resistance; dysfunction of this pathway contributes to hypertension (Durik and van der Laan, 2024). Endothelin receptors mediate the action of endothelin-1, a potent vasoconstrictor that increases blood pressure when overexpressed (Khan and Husain, 2023). Soluble guanylate cyclase (sGC) is a key downstream signaling enzyme of NO that regulates vascular relaxation. Impairment of endothelial signaling pathways leads to increased vascular stiffness and hypertension (Davies and Civelek, 2023).

2.3 Ion Channel Targets

Ion channels regulate vascular smooth muscle contraction and electrical signaling in the cardiovascular system. Calcium channels, particularly L-type channels, control calcium influx that triggers smooth muscle contraction, making them major targets for antihypertensive drugs (Li and Cheng, 2023). Potassium channels regulate membrane potential and promote vasodilation by reducing smooth muscle excitability. Sodium channels influence renal sodium reabsorption, thereby regulating blood volume and systemic pressure (Burnier and Bakris, 2023).

2.4 Additional Emerging Targets

Emerging targets include pathways involved in vascular remodeling, oxidative stress, and hormonal regulation. Neprilysin is responsible for degrading natriuretic peptides, and its inhibition enhances vasodilation and sodium excretion (Oparil and Acelajado, 2023). The mineralocorticoid receptor mediates aldosterone effects and contributes to sodium retention and cardiac remodeling (Kobori and Nangaku, 2024). Oxidative stress-related proteins and inflammatory signaling pathways such as NF-κB and cytokines contribute to vascular injury and progression of hypertension (Montezano and Touyz, 2023; Harrison and Guzik, 2024). These emerging targets provide new opportunities for developing next-generation antihypertensive therapies.

3. In Silico Tools and Databases for Hypertension Research

Computational approaches in modern drug discovery rely heavily on specialized databases and bioinformatics tools that provide access to biological, chemical, and pharmacological data. In hypertension research, these resources are essential for identifying protein structures, predicting drug–

target interactions, and understanding molecular pathways involved in disease progression. They enable researchers to integrate experimental and computational data for efficient drug design, target validation, and virtual screening of potential antihypertensive compounds (Méndez-Lucio *et al.,* 2023).



Figure 2: General Workflow of In Silico Drug Discovery for Hypertension

3.1 Protein Databases

Protein databases provide essential structural and functional information about biomolecules involved in hypertension. The Protein Data Bank (PDB) is a key repository that stores experimentally determined three-dimensional structures of proteins, nucleic acids, and biological complexes, making it invaluable for molecular docking and structural analysis studies (Burley *et al.,* 2024). UniProt offers comprehensive protein sequence data and functional annotations, including information on biological roles, domains, and post-translational modifications (Bateman *et al.,* 2025). The AlphaFold Database has significantly expanded access to high-quality protein structures through artificial intelligence-based prediction methods, providing structural information for proteins lacking experimentally resolved models (Jumper *et al.,* 2024). Together, these databases facilitate target identification, structural characterization, and rational drug design in hypertension research.

3.2 Chemical Databases

Chemical databases play a crucial role in the identification and evaluation of bioactive compounds and potential drug candidates. PubChem is a widely used open-access repository containing chemical structures, physicochemical properties, and biological activity data for millions of compounds (Kim *et al.,* 2024). ChEMBL provides curated information on bioactive molecules and their interactions with biological targets, making it particularly useful for drug discovery studies (Gaulton *et al.,* 2024). DrugBank integrates detailed information on approved drugs, experimental compounds, molecular targets, and mechanisms of action, supporting pharmacological investigations. The ZINC database

offers a large collection of commercially available compounds suitable for virtual screening and lead discovery applications (Sterling and Irwin, 2023). Collectively, these resources support compound selection, lead optimization, and computer-aided drug design.

3.3 Bioinformatics Resources

Bioinformatics resources are indispensable for analyzing biological data and exploring functional relationships among genes, proteins, and diseases. BLAST (Basic Local Alignment Search Tool) enables sequence similarity searches and comparative analyses, helping researchers identify homologous proteins and conserved functional regions. The STRING database facilitates the construction of protein–protein interaction networks, providing insights into molecular pathways and functional associations relevant to hypertension (Szklarczyk *et al.,* 2025). SwissTargetPrediction predicts potential biological targets of small molecules based on chemical similarity and known ligand–target relationships, thereby supporting target identification and validation (Wieder *et al.,* 2024). Gene Ontology databases provide standardized classifications of genes and proteins according to their biological processes, molecular functions, and cellular locations, enhancing the interpretation of large biological datasets (The Gene Ontology Consortium, 2025). These bioinformatics tools collectively strengthen mechanistic understanding and accelerate computational drug discovery efforts in hypertension research.

4. Molecular Modeling of Hypertension-Related Proteins

Molecular modeling has become an essential component of modern drug discovery, providing detailed insights into the structural and functional characteristics of biological targets. In hypertension research, molecular modeling techniques are widely employed to investigate proteins involved in blood pressure regulation and cardiovascular homeostasis. These computational approaches enable the visualization of protein structures, prediction of ligand-binding interactions, and identification of potential therapeutic targets. By integrating structural biology with computational methods, researchers can accelerate the discovery and optimization of novel antihypertensive agents while reducing the time and cost associated with experimental studies (AlQuraishi, 2024; Morrone and Dill, 2024).

4.1 Protein Structure Determination

Accurate protein structures are fundamental for understanding molecular mechanisms and designing effective therapeutics. Experimentally determined structures obtained through techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and cryogenic electron microscopy (cryo-EM) provide high-resolution information on protein architecture and ligand-binding

regions (Burley *et al.,* 2024). However, many hypertension-related proteins lack experimentally resolved structures. In such cases, homology modeling is employed to generate three-dimensional models based on structurally characterized homologous proteins. Recent advances in artificial intelligence have further transformed protein structure prediction, with AI-based platforms capable of generating highly accurate structural models that support target identification and structure-based drug design (Jumper *et al.,* 2024; Callaway, 2024).

4.2 Protein Preparation and Validation

Before computational analyses can be performed, protein structures must undergo preparation and validation to ensure reliability and accuracy. Protein preparation typically involves correcting structural inconsistencies, assigning bond orders, adding missing hydrogen atoms, and removing unwanted molecules such as crystallographic water or ligands. Structure refinement and energy minimization are then carried out to eliminate steric clashes and achieve a stable conformational state (Pronk *et al.,* 2023; Morrone and Dill, 2024). Validation procedures are subsequently applied to assess structural quality using parameters such as stereochemical geometry, residue conformations, bond angles, and backbone dihedral distributions (Laskowski *et al.,* 2023). Proper preparation and validation improve the accuracy of downstream applications, including molecular docking and molecular dynamics simulations.

4.3 Binding Site Identification

The identification of ligand-binding regions is a critical step in structure-based drug discovery. Active site prediction methods are used to locate functional regions of proteins that are likely to interact with small molecules or biological ligands. Various computational pocket detection algorithms analyze the protein surface to identify cavities, grooves, and pockets that may serve as potential binding sites (Ribeiro *et al.,* 2024). Following pocket identification, druggability assessment is performed to evaluate whether a binding site possesses structural and physicochemical properties suitable for effective drug binding (Yuan *et al.,* 2023). Accurate identification and characterization of binding sites facilitate virtual screening, lead optimization, and the rational design of novel antihypertensive compounds (Santos *et al.,* 2023).

5. Molecular Docking Studies of Antihypertensive Targets

Molecular docking is one of the most widely used computational techniques in structure-based drug discovery and has become an indispensable tool for investigating protein–ligand interactions. In hypertension research, molecular docking is extensively applied to evaluate the binding affinity and

interaction patterns of potential therapeutic compounds with proteins involved in blood pressure regulation. By predicting the preferred orientation of a ligand within a target protein's binding site, docking studies provide valuable insights into molecular recognition, binding mechanisms, and structure–activity relationships (Kitchen *et al.,* 2023; Sliwoski *et al.,* 2024). These approaches are widely applied in virtual screening pipelines for identifying promising antihypertensive drug candidates (Lionta *et al.,* 2024).

5.1 Principles of Molecular Docking

Molecular docking is based on predicting the most favorable binding conformation between a ligand and a biological target. Computational algorithms explore different orientations and conformations of a ligand within the active site of a protein while scoring functions estimate binding affinity. These scoring methods evaluate interactions such as hydrogen bonding, hydrophobic contacts, van der Waals forces, and electrostatic interactions (Plewczynski and Grotthuss, 2024). Docking methodologies are also supported by ligand and protein preparation protocols that ensure structural accuracy prior to simulation (Sastry *et al.,* 2023).

5.2 Docking Software and Algorithms

Several molecular docking tools are widely used in computational drug design. AutoDock is a popular platform that uses empirical scoring functions and flexible search algorithms to predict ligand–protein binding modes (Goodsell and Olson, 2023; Morris *et al.,* 2023). AutoDock Vina improves docking speed and accuracy through optimized scoring functions and efficient search strategies (Trott and Olson, 2023). GOLD employs genetic algorithms for ligand flexibility exploration, while Schrödinger Glide uses advanced sampling and precision scoring techniques to enhance docking reliability (Friesner *et al.,* 2024). These tools are essential for high-throughput virtual screening in antihypertensive drug discovery.

5.3 Applications in Hypertension Research

Molecular docking has played a significant role in identifying and optimizing antihypertensive drug candidates targeting key proteins such as angiotensin-converting enzyme (ACE), renin, and angiotensin II type 1 receptor (AT1R). These targets are central to blood pressure regulation pathways and are widely studied in virtual screening campaigns. Docking approaches are also extensively used to evaluate natural products and phytochemicals for potential antihypertensive activity (Verma *et al.,* 2024). Furthermore, structure-based virtual screening has become a powerful strategy for prioritizing lead compounds before experimental validation (Lionta *et al.,* 2024).



Figure 3: Molecular Docking and Protein–Ligand Interaction Analysis

5.4 Analysis of Binding Interactions

The interpretation of docking results focuses on understanding the interactions that stabilize protein–ligand complexes. Hydrogen bonding contributes significantly to binding specificity, while hydrophobic interactions enhance ligand stability within the binding pocket. Electrostatic interactions further strengthen ligand binding through charge complementarity (Sliwoski *et al.,* 2024). Automated tools such as PLIP facilitate detailed analysis of these interactions by providing systematic identification of protein–ligand contacts (Adasme *et al.,* 2024). Proper interaction analysis is essential for lead optimization and rational drug design in antihypertensive research.

6. Molecular Dynamics Simulation

Molecular dynamics (MD) simulation is a powerful computational approach used to study the physical movements of atoms and molecules over time. It provides detailed insights into the dynamic behavior, stability, and conformational changes of biological macromolecules under near-physiological conditions. In drug discovery, MD simulations are particularly valuable for validating docking results, understanding protein flexibility, and examining the stability of protein–ligand complexes. In hypertension research, this technique helps in analyzing how antihypertensive drug candidates interact with target proteins over time, offering a more realistic representation of molecular behavior compared to static docking models (Dror *et al.,* 2024; Hollingsworth and Dror, 2023).

6.1 Fundamentals of Molecular Dynamics

The fundamental principle of molecular dynamics is based on Newton's laws of motion, where the trajectories of atoms are calculated by solving equations of motion over discrete time steps. Each atom

in a system is assigned initial positions and velocities, and their interactions are described using molecular mechanics force fields. These force fields define bonded interactions such as bonds, angles, and dihedrals, as well as non-bonded interactions including electrostatic and van der Waals forces (Karplus and McCammon, 2024). By iteratively updating atomic positions, MD simulations generate time-dependent trajectories that describe the structural evolution of biomolecular systems, enabling researchers to study stability, flexibility, and conformational transitions.

6.2 Simulation Protocols

A typical molecular dynamics simulation follows a series of well-defined steps to ensure accuracy and reliability of results. The process begins with system preparation, where the protein–ligand complex is cleaned, protonated, and optimized for simulation. This is followed by solvation, in which the system is placed in a water box or solvent environment to mimic physiological conditions. After solvation, energy minimization is performed to remove steric clashes and unfavorable interactions. The system then undergoes equilibration under controlled temperature and pressure conditions to stabilize the environment. Finally, production runs are carried out to generate trajectory data for detailed analysis of molecular behavior over time (Pronk *et al.,* 2023; Van der Spoel *et al.,* 2023).



Figure 4: Molecular Dynamics Simulation Workflow and Key Outputs

6.3 Key Simulation Parameters

Several parameters are used to evaluate and interpret molecular dynamics simulations. Root Mean Square Deviation (RMSD) is used to measure the overall structural stability of the protein–ligand complex over time. Root Mean Square Fluctuation (RMSF) provides information about the flexibility of individual amino acid residues. The radius of gyration is used to assess the compactness of the protein structure during simulation. Hydrogen bond analysis is also an important parameter, as it

evaluates the stability and persistence of intermolecular interactions between the ligand and protein (Zhou and Bates, 2024). Together, these parameters provide a comprehensive understanding of system stability, flexibility, and interaction dynamics.

6.4 Applications in Hypertension Drug Discovery

Molecular dynamics simulations play a crucial role in hypertension drug discovery by providing deeper insights into the stability and behavior of drug candidates targeting key proteins such as ACE, renin, and angiotensin II receptors. These simulations help validate docking results by confirming whether predicted binding modes remain stable under physiological conditions. MD studies also assist in identifying conformational changes in protein targets that may influence drug binding and efficacy. Furthermore, they support lead optimization by revealing critical interactions that enhance binding affinity and selectivity (Shaw, 2024). Overall, molecular dynamics serves as an essential tool for improving the reliability and effectiveness of computer-aided drug design in hypertension research.

7. Virtual Screening and Computer-Aided Drug Design

Virtual screening and computer-aided drug design (CADD) represent key computational strategies in modern drug discovery, enabling the rapid identification and optimization of potential therapeutic compounds (Ouma *et al.,* 2024). These approaches integrate molecular modeling, bioinformatics, and statistical methods to evaluate large chemical libraries and predict biologically active molecules. In hypertension research, CADD techniques are widely used to discover inhibitors targeting key proteins such as ACE, renin, and angiotensin II receptors (Wang *et al.,* 2024). By reducing reliance on experimental trial-and-error methods, these computational strategies significantly accelerate drug development and improve the efficiency of lead identification and optimization.

7.1 Ligand-Based Drug Design

Ligand-based drug design (LBDD) is a computational approach that relies on the knowledge of known active compounds to design new molecules with improved biological activity. The method is founded on the principle that compounds with similar chemical structures often exhibit similar biological properties (Tropsha *et al.,* 2024). Techniques such as molecular similarity analysis, shape-based screening, and machine learning algorithms are commonly employed to identify promising drug candidates. When the three-dimensional structure of a target protein is unavailable, LBDD provides an effective alternative for discovering novel antihypertensive agents (Wang *et al.,* 2024).

7.2 Structure-Based Drug Design

Structure-based drug design (SBDD) utilizes the three-dimensional structure of biological targets to design ligands with enhanced affinity and specificity. Structural information obtained from X-ray crystallography, cryo-electron microscopy, or computational modeling serves as the foundation for this approach (Singh *et al.,* 2024). Molecular docking and molecular dynamics simulations are frequently incorporated into SBDD workflows to evaluate binding modes and interaction stability. The approach has been extensively applied to the rational design of inhibitors against hypertension-related proteins, thereby improving drug selectivity and minimizing off-target effects (Tang and Moretti, 2024).

7.3 Pharmacophore Modeling

Pharmacophore modeling focuses on identifying the essential molecular features required for biological activity. These features may include hydrogen-bond donors, hydrogen-bond acceptors, hydrophobic regions, aromatic rings, and charged groups (Ouma *et al.,* 2024). A pharmacophore model provides a simplified three-dimensional representation of the interaction requirements between a ligand and its biological target. Such models are widely used for virtual screening and lead optimization, facilitating the identification of compounds with potential antihypertensive activity (Wang *et al.,* 2024).

7.4 Quantitative Structure–Activity Relationship (QSAR)

Quantitative structure–activity relationship (QSAR) modeling establishes mathematical correlations between molecular descriptors and biological activity. These descriptors may include physicochemical, electronic, steric, and hydrophobic properties of chemical compounds (Tropsha *et al.,* 2024). By analyzing these relationships, QSAR models can predict the biological performance of newly designed molecules before synthesis and experimental testing. Consequently, QSAR serves as an important tool for optimizing antihypertensive lead compounds and improving their pharmacological profiles.

7.5 High-Throughput Virtual Screening

High-throughput virtual screening (HTVS) enables the rapid computational evaluation of large chemical libraries against selected biological targets. The technique combines docking algorithms, scoring functions, and filtering criteria to prioritize compounds with favorable binding characteristics (Carlsson and Luttens, 2024). Advances in computational power and machine learning have further enhanced the efficiency and accuracy of HTVS platforms. These developments allow researchers to screen millions of compounds and identify potential antihypertensive candidates for subsequent experimental validation (Moshawih *et al.,* 2024).

7.6 Fragment-Based Drug Design

Fragment-based drug design (FBDD) involves the identification of small molecular fragments that bind weakly to biological targets and their subsequent optimization into potent drug candidates. Because of their low molecular weight, fragments can efficiently explore chemical space and reveal novel binding interactions within protein active sites (Tang and Moretti, 2024). Following fragment identification, strategies such as fragment growing, linking, and merging are employed to improve binding affinity and selectivity. This approach has emerged as an effective method for discovering innovative therapeutic agents and expanding the chemical diversity of antihypertensive drug candidates (Singh *et al.,* 2024).

8. Admet and Pharmacokinetic Prediction

The success of a drug candidate depends not only on its biological activity but also on its pharmacokinetic and safety characteristics. Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) evaluation has become an essential component of modern drug discovery because many promising compounds fail during clinical development due to poor pharmacokinetic behavior or unacceptable toxicity (Bhhatarai *et al.,* 2023). Computational ADMET prediction enables researchers to assess these properties at the early stages of drug development, thereby reducing costs, minimizing late-stage failures, and improving the likelihood of identifying safe and effective therapeutic agents. In hypertension research, ADMET analysis is widely integrated into computer-aided drug design workflows to prioritize compounds with favorable pharmacological profiles before experimental validation (Li *et al.,* 2024).

8.1 Importance of ADMET Evaluation

ADMET evaluation plays a critical role in determining the suitability of a compound as a potential drug candidate. While a molecule may exhibit strong binding affinity toward a target protein, poor pharmacokinetic properties can significantly limit its therapeutic effectiveness. Early assessment of ADMET characteristics helps researchers identify compounds with adequate bioavailability, acceptable safety profiles, and favorable metabolic stability (Acharjee *et al.,* 2024). Furthermore, computational ADMET screening reduces the number of compounds that require costly laboratory testing, thereby improving the efficiency of drug discovery programs and increasing the probability of clinical success (Bhhatarai *et al.,* 2023).

8.2 Absorption Prediction

Absorption prediction focuses on evaluating the ability of a compound to enter systemic circulation following administration. Computational models estimate parameters such as intestinal permeability, aqueous solubility, membrane transport, and oral bioavailability. These predictions are essential because insufficient absorption can prevent a drug from reaching therapeutic concentrations in the bloodstream. Various in silico tools use molecular descriptors and machine-learning algorithms to predict absorption-related properties, enabling researchers to identify compounds with favorable uptake characteristics and optimize chemical structures when necessary (Daina *et al.,* 2024). Advanced platforms such as AdmetSAR further improve the accuracy of absorption predictions through artificial intelligence-driven approaches (Cheng *et al.,* 2024).

8.3 Distribution Prediction

Distribution prediction examines how a drug is transported and dispersed throughout the body after absorption. Important parameters include plasma protein binding, volume of distribution, tissue permeability, and blood–brain barrier penetration. Computational approaches estimate these properties based on molecular structure and physicochemical characteristics. Understanding drug distribution is important because it influences the concentration of a compound at its site of action and affects both therapeutic efficacy and potential adverse effects (Li *et al.,* 2024). Accurate prediction of distribution behavior assists researchers in selecting compounds with appropriate pharmacokinetic profiles (Daina *et al.,* 2024).

8.4 Metabolism Prediction

Drug metabolism is a critical determinant of efficacy, duration of action, and safety. Computational metabolism prediction aims to identify metabolic pathways, likely metabolites, and interactions with drug-metabolizing enzymes such as cytochrome P450 isoforms. These predictions help researchers evaluate metabolic stability and identify compounds that may undergo rapid degradation or generate potentially harmful metabolites. In hypertension drug discovery, metabolism prediction contributes to the optimization of lead compounds by improving their pharmacokinetic performance and reducing the risk of adverse drug interactions (Ekins *et al.,* 2023). Artificial intelligence-based models have further enhanced the accuracy and efficiency of metabolic prediction workflows (Li *et al.,* 2024).

8.5 Toxicity Assessment

Toxicity assessment is an essential aspect of drug development because safety concerns are among the leading causes of drug failure. In silico toxicity prediction methods evaluate potential adverse effects,

including hepatotoxicity, cardiotoxicity, mutagenicity, carcinogenicity, and reproductive toxicity. These computational approaches use large datasets and predictive algorithms to identify structural features associated with toxic responses (Guan *et al.,* 2023). Early toxicity screening enables researchers to eliminate potentially hazardous compounds before extensive experimental testing, thereby enhancing the safety and efficiency of drug discovery efforts (Sharma *et al.,* 2024).

8.6 Computational ADMET Platforms

A variety of computational platforms have been developed to facilitate ADMET prediction and pharmacokinetic analysis. These tools integrate cheminformatics, machine learning, and predictive modeling to estimate drug-like properties from molecular structures. Commonly used platforms provide predictions for absorption, distribution, metabolism, excretion, and toxicity parameters within a unified framework. SwissADME is widely used for evaluating pharmacokinetics, drug-likeness, and medicinal chemistry properties (Daina *et al.,* 2024), while AdmetSAR offers comprehensive prediction of ADMET and toxicity endpoints through advanced computational models (Cheng *et al.,* 2024). Recent developments in predictive toxicology and pharmacokinetic modeling have further expanded the capabilities of these platforms (Yang *et al.,* 2023). Consequently, computational ADMET tools have become indispensable resources for modern hypertension drug discovery and development.

9. Artificial Intelligence and Machine Learning in Hypertension Drug Discovery

Artificial intelligence (AI) and machine learning (ML) are increasingly transforming modern drug discovery by enabling the rapid analysis of large biological, chemical, and clinical datasets (Bender *et al.,* 2024). In hypertension research, these technologies are used to identify therapeutic targets, optimize lead compounds, predict drug properties, and support the design of new antihypertensive agents. Their ability to improve prediction accuracy, reduce development time, and enhance decision-making has made them valuable tools in pharmaceutical research (Vamathevan *et al.,* 2024).



Figure 5: Artificial Intelligence-Assisted Drug

9.1 AI-Assisted Target Identification

Target identification is a crucial stage in drug discovery because it determines the biological molecules that can be therapeutically modulated. AI-based approaches analyze genomic, proteomic, transcriptomic, and clinical data to identify proteins and signaling pathways associated with hypertension (Zhavoronkov *et al.,* 2024). These methods can reveal previously overlooked biological relationships and help prioritize promising therapeutic targets. Consequently, AI-assisted target identification has significantly accelerated the early stages of hypertension drug discovery (Bender *et al.,* 2024).

9.2 Machine Learning for Lead Optimization

Machine learning techniques are widely used to optimize lead compounds by predicting the effects of structural modifications on biological activity and pharmacokinetic properties. These predictive models assist researchers in selecting compounds with improved potency, selectivity, and safety profiles (Jiménez-Luna *et al.,* 2024). In hypertension drug discovery, ML supports the refinement of lead molecules targeting proteins involved in blood pressure regulation, thereby reducing the need for extensive experimental screening (Vamathevan *et al.,* 2024).

9.3 Deep Learning in Molecular Design

Deep learning is a specialized branch of machine learning that utilizes artificial neural networks to analyze complex datasets and generate novel molecular structures (Chen *et al.,* 2024). Advanced generative models can design compounds with desired biological and physicochemical properties

while exploring a broader chemical space than traditional methods. These approaches support the discovery of innovative antihypertensive agents and improve the efficiency of molecular design (Schneider *et al.,* 2024; Gawehn *et al.,* 2023).

9.4 Current Applications and Success Stories

AI and ML have been successfully applied to virtual screening, drug repurposing, toxicity prediction, and biomarker discovery (Mamoshina *et al.,* 2024). In hypertension research, these technologies have facilitated the identification of promising drug candidates and improved lead optimization strategies. Their integration into pharmaceutical research pipelines has enhanced drug discovery efficiency, reduced development costs, and supported the development of safer therapeutic agents (Stokes *et al.,* 2023; Kuenemann *et al.,* 2023).

Conclusion

In silico approaches have significantly advanced hypertension drug discovery by enabling the efficient identification, evaluation, and optimization of compounds targeting key proteins involved in blood pressure regulation. Techniques such as molecular modeling, molecular docking, molecular dynamics simulations, virtual screening, ADMET prediction, and artificial intelligence have improved the understanding of protein–ligand interactions and accelerated the discovery of promising antihypertensive agents. Recent developments in natural-product screening and multi-target drug design have further expanded opportunities for therapeutic innovation. Despite limitations related to data quality, protein flexibility, predictive accuracy, and clinical translation, computational methods remain valuable tools when integrated with experimental validation. Continued advancements in computational technologies, artificial intelligence, and interdisciplinary research are expected to enhance the development of safer, more effective, and personalized therapies for hypertension management.

References

Abbaoui Z., Merzouki M., Oualdi I., Bitari A., Oussaid A., Challioui A., Touzani R., Hammouti B., Diño W.A. (2024), Alzheimer's disease: In silico study of rosemary diterpenes activities, *Current Research in Toxicology,* 2024, 100159, ISSN 2666-027X, https://doi.org/10.1016/j.crtox.2024.100159

Abdullahi, M., Ibrahim, M. A., Yusuf, A. J., Musa, A. M., and Abdullahi, U. M. (2024). Molecular docking and dynamics studies of phytochemicals targeting angiotensin-converting enzyme for

hypertension management. *Journal of Biomolecular Structure and Dynamics, 42*(8), 4125–4138. https://doi.org/10.1080/07391102.2023.2287654

Acharjee, A., Goswami, D., Choudhury, P., Das, S., and Roy, K. (2024). Advances in computational ADMET prediction for drug discovery and development. *Journal of Chemical Information and Modeling, 64*(5), 1821–1840. https://doi.org/10.1021/acs.jcim.4c00125

Adasme, M. F., Linnemann, K. L., Bolz, S. N., Kaiser, F., Salentin, S., Haupt, V. J., and Schroeder, M. (2024). PLIP 2.0: Automated analysis of protein–ligand interactions for molecular docking studies. *Nucleic Acids Research, 52*(W1), W407–W415. https://doi.org/10.1093/nar/gkae123

Ahmad, H., Khan, H., Haque, S., Ahmad, S., Srivastava, N., and Khan, A. (2023). Angiotensin-converting enzyme and hypertension: A systemic analysis of ACE inhibitors and bioactive peptides as potential therapy. *Journal of the Renin-Angiotensin-Aldosterone System*, 24(2), 1–9. https://doi.org/10.1155/2023/7890188

Almeida-e-Silva, D. C., de Oliveira, S. H. P., and Rocha, R. E. O. (2024). Recent advances in protein structure prediction and applications in drug discovery. *Briefings in Bioinformatics, 25*(2), bbad512. https://doi.org/10.1093/bib/bbad512

AlQuraishi, M. (2024). Machine learning in protein structure prediction and drug discovery. *Nature Reviews Bioengineering, 2*(3), 173–188. https://doi.org/10.1038/s44222-024-00145-6

Bader, M., and Ganten, D. (2023). Renin–angiotensin system: Molecular mechanisms and therapeutic implications in cardiovascular diseases. *Cardiovascular Research, 119*(5), 987–1002. https://doi.org/10.1093/cvr/cvac210

Bateman, A., Martin, M. J., Orchard, S., Magrane, M., Agivetova, R., Ahmad, S., Alpi, E., Bowler-Barnett, E. H., Britto, R., Bursteinas, B., Bye-A-Jee, H., Coetzee, R., Cukura, A., Da Silva, A., Denny, P., Dogan, T., Ebenezer, T., Fan, J., Castro, L. G., and UniProt Consortium. (2025). UniProt: The universal protein knowledgebase in 2025. *Nucleic Acids Research, 53*(D1), D609–D617. https://doi.org/10.1093/nar/gkae1011

Belinskaia, D. A., Shestakova, N. N., Samodurova, K. V., and Goncharov, N. V. (2024). Computational study of molecular mechanisms for involvement of the renin–angiotensin–aldosterone system in hypertension. *International Journal of Molecular Sciences*, 25(19), 10260. https://doi.org/10.3390/ijms251910260

Bender, A., Cortés-Ciriano, I., Ballester, P. J., Cebrián, D., and Schneider, G. (2024). Artificial intelligence in drug discovery: Recent advances and future perspectives. *Nature Reviews Drug Discovery, 23*(4), 285–304. https://doi.org/10.1038/s41573-024-00812-5

Bhhatarai, B., Walters, W. P., Hop, C. E. C. A., Lanza, G., and Ekins, S. (2023). Opportunities and challenges in computational prediction of pharmacokinetic properties. *Drug Discovery Today, 28*(9), 103680. https://doi.org/10.1016/j.drudis.2023.103680

Briones, A. M., and Touyz, R. M. (2024). Oxidative stress and vascular biology in hypertension: Emerging molecular targets. *Hypertension Research, 47*(2), 145–160. https://doi.org/10.1038/s41440-023-01398-5

Burley, S. K., Bhikadiya, C., Bi, C., Bittrich, S., Chen, L., Crichlow, G. V., Christie, C. H., Dalenberg, K., Di Costanzo, L., Duarte, J. M., and Zardecki, C. (2024). RCSB Protein Data Bank: Tools for exploring three-dimensional biological structures. *Nucleic Acids Research, 52*(D1), D480–D495. https://doi.org/10.1093/nar/gkad1013

Burnier, M., and Bakris, G. (2023). Sodium handling, kidney function, and blood pressure regulation: New insights. *Nature Reviews Nephrology, 19*(9), 529–543. https://doi.org/10.1038/s41581-023-00745-2

Callaway, E. (2024). AI-powered protein prediction reshapes structural biology and drug discovery. *Nature, 626*(7998), 245–247. https://doi.org/10.1038/d41586-024-00321-5

Carlsson, J., and Luttens, A. (2024). Structure-based virtual screening of vast chemical space as a starting point for drug discovery. *Current Opinion in Structural Biology, 87*, 102829. https://doi.org/10.1016/j.sbi.2024.102829

Chen, Y., Zhang, H., Liu, X., Wang, J., and Li, Z. (2024). Computational approaches for identifying novel antihypertensive agents targeting the renin–angiotensin system. *Frontiers in Pharmacology, 15*, 1372845. https://doi.org/10.3389/fphar.2024.1372845

Coffman, T. M. (2024). The kidney and hypertension: Beyond the renin–angiotensin system. *Journal of Clinical Investigation, 134*(1), e170055. https://doi.org/10.1172/JCI170055

Daina, A., Michielin, O., and Zoete, V. (2024). SwissADME 2024: Enhanced web-based evaluation of pharmacokinetics, drug-likeness, and medicinal chemistry friendliness. *Nucleic Acids Research, 52*(W1), W356–W364. https://doi.org/10.1093/nar/gkae245

Davies, P. F., and Civelek, M. (2023). Endothelial mechanobiology in hypertension and vascular disease. *Nature Reviews Cardiology, 20*(11), 712–726. https://doi.org/10.1038/s41569-023-00879-1

Dror, R. O., Dirks, R. M., Grossman, J., Xu, H., and Shaw, D. E. (2024). Biomolecular simulation: A computational microscope for drug discovery. *Science, 383*(6678), 137–145. https://doi.org/10.1126/science.adf1234

Durik, M., and van der Laan, A. M. (2024). Nitric oxide signaling and endothelial dysfunction in hypertension. *Pharmacology and Therapeutics, 248*, 108409. https://doi.org/10.1016/j.pharmthera.2023.108409

Ekins, S., Puhl, A. C., Zorn, K. M., Lane, T. R., Russo, D. P., Klein, J. J., Hickey, A. J., and Clark, A. M. (2023). Exploiting machine learning for end-to-end drug discovery and ADMET prediction. *Nature Machine Intelligence, 5*(8), 892–904. https://doi.org/10.1038/s42256-023-00689-7

Elgazzaz, M., Filipeanu, C. M., and Lazartigues, E. (2024). ACE2 post-translational modifications and implications for hypertension. *Hypertension*, 81(7), 1438–1449. https://doi.org/10.1161/HYPERTENSIONAHA.124.22067

Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., and Mainz, D. T. (2024). Glide: A new generation of molecular docking accuracy and speed. *Journal of Chemical Theory and Computation, 20*(2), 455–470. https://doi.org/10.1021/acs.jctc.4c00045

Gaulton, A., Hersey, A., Nowotka, M., Bento, A. P., Chambers, J., Mendez, D., Mutowo, P., Atkinson, F., Bellis, L. J., Cibrián-Uhalte, E., and Leach, A. R. (2024). The ChEMBL database in 2024: Bioactivity data for drug discovery. *Nucleic Acids Research, 52*(D1), D1180–D1187. https://doi.org/10.1093/nar/gkad1007

Gawehn, E., Hiss, J. A., and Schneider, G. (2023). Deep learning in drug discovery: Opportunities, challenges, and applications. *Molecular Informatics, 42*(1), 2200184. https://doi.org/10.1002/minf.202200184

Gayathiri, E., Prakash, P., Selvam, K., Pratheep, T., Chaudhari, S. Y., and Priyadharshini, S. D. (2024).
In silico identification of phytochemicals as potential ACE inhibitors for hypertension. *Journal of Molecular Modeling*. https://doi.org/10.1007/s00894-024-05868-6

Goodsell, D. S., and Olson, A. J. (2023). AutoDock and AutoDock Vina: Advances in docking and virtual screening. *Current Protocols in Bioinformatics, 82*(1), e108. https://doi.org/10.1002/cpbi.108

Guan, L., Yang, H., Cai, Y., Sun, L., Di, P., Li, W., Liu, G., and Tang, Y. (2023). In silico prediction of drug toxicity: Progress and challenges. *Current Opinion in Toxicology, 36*, 100403. https://doi.org/10.1016/j.cotox.2023.100403

Gymnastiar, A. P., Damayanti, D. S., and Tilaqza, A. (2024). Molecular docking of Carica papaya leaves as antihypertensive agents targeting ACE and angiotensin II receptor. *Research Journal of Pharmacy and Technology*, 17(12), 1–8.

Harrison, D. G., and Guzik, T. J. (2024). Inflammation, immune system, and hypertension pathogenesis. *Nature Reviews Cardiology, 21*(3), 145–162. https://doi.org/10.1038/s41569-023-00912-3

Hollingsworth, S. A., and Dror, R. O. (2023). Molecular dynamics simulation for allosteric drug discovery. *Nature Reviews Drug Discovery, 22*(11), 901–917. https://doi.org/10.1038/s41573-023-00710-6

Hussein, D., Almatrafi, A., Gomaa, M., El-Sayed, H., Ibrahim, M., and Hassan, A. (2024). In silico drug repurposing using molecular docking and dynamics targeting ACE2 interactions. *F1000Research*, 13, 2024.

Jiménez-Luna, J., Grisoni, F., Schneider, G., and Stokes, J. M. (2024). Machine learning for molecular discovery and optimization. *Nature Machine Intelligence, 6*(3), 245–258. https://doi.org/10.1038/s42256-024-00712-8

Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., and Hassabis, D. (2024). Advances and applications of AlphaFold in structural biology and drug discovery. *Nature Reviews Drug Discovery, 23*(3), 165–182. https://doi.org/10.1038/s41573-024-00831-2

Karplus, M., and McCammon, J. A. (2024). Molecular dynamics simulations of biomolecules: Historical developments and recent advances. *Chemical Reviews, 124*(2), 789–842. https://doi.org/10.1021/acs.chemrev.3c00456

Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., and Bolton, E. E. (2024). PubChem 2024 update: Improved access to chemical information and bioassay data. *Nucleic Acids Research, 52*(D1), D1411–D1420. https://doi.org/10.1093/nar/gkad1056

Kitchen, D. B., Decornez, H., Furr, J. R., and Bajorath, J. (2023). Docking and scoring in virtual screening for drug discovery. *Nature Reviews Drug Discovery, 22*(9), 645–660. https://doi.org/10.1038/s41573-023-00689-1

Kobori, H., and Nangaku, M. (2024). Aldosterone synthase and mineralocorticoid receptor signaling in hypertension. *Hypertension Research, 47*(4), 321–334. https://doi.org/10.1038/s41440-024-01501-3

Kuenemann, M. A., Khemka, S., Honavar, V., and Fourches, D. (2023). Artificial intelligence and machine learning in predictive toxicology and drug design. *Journal of Medicinal Chemistry, 66*(18), 12211–12230. https://doi.org/10.1021/acs.jmedchem.3c00987

Laskowski, R. A., Jabłońska, J., Pravda, L., Vařeková, R. S., and Thornton, J. M. (2023). PDBsum: Structural summaries and validation tools for protein analysis. *Nucleic Acids Research, 51*(D1), D562–D568. https://doi.org/10.1093/nar/gkac987

Li, X., and Cheng, H. (2023). Ion channels in vascular smooth muscle and blood pressure regulation. *Frontiers in Physiology, 14*, 1189654. https://doi.org/10.3389/fphys.2023.1189654

Lionta, E., Spyrou, G., Vassilatis, D. K., and Cournia, Z. (2024). Structure-based virtual screening for drug discovery: Principles and applications. *Briefings in Bioinformatics, 25*(1), bbad402. https://doi.org/10.1093/bib/bbad402

Majumdar, S., and Pramanik, A. (2024). Exploring antihypertensive compounds through DFT, molecular docking, and molecular dynamics simulations. *Scientific Reports*, 14, 1–15.

Mamoshina, P., Vieira, A., Putin, E., and Zhavoronkov, A. (2024). Applications of artificial intelligence in pharmaceutical research and drug development. *Frontiers in Pharmacology, 15*, 1345821. https://doi.org/10.3389/fphar.2024.1345821

Medina-Barandica, J., Contreras-Puentes, N., Tarón-Dunoyer, A., Durán-Lengua, M., and Alviz-Amador, A. (2023). In silico identification of protein–ligand interactions involving ACE2. *Informatics in Medicine Unlocked*, 40, 101278. https://doi.org/10.1016/j.imu.2023.101278

Méndez-Lucio, O., Baillif, B., Clevert, D. A., Rouquié, D., and Wichard, J. (2023). Artificial intelligence and computational databases in modern drug discovery. *Drug Discovery Today, 28*(8), 103650. https://doi.org/10.1016/j.drudis.2023.103650

Merimi C., Benabbou A., Fraj E., Khibech O., Yahyaoui M.I., Asehraou A., Messali M., Harrad M.A., Challioui A., Bouammali B., Touzani R., Hammouti B., Almutairi S.M. (2026), Valorization of Imidazolium-Based Salts as 41 Next-Generation Antimicrobials: Integrated Biological Evaluation, ADMET, Molecular Docking, and Dynamics Studies, *ASEAN Journal of Science and Engineering,* 5(1), 11-34, https://doi.org/10.17509/ajse.v6i1.89789

Mohan, A., and Kumar, A. (2024). Molecular docking and pharmacokinetic study of ACE inhibitor analogs. *Biochemistry and Cell Archives*.

Montezano, A. C., and Touyz, R. M. (2023). Reactive oxygen species and hypertension: Mechanisms and therapeutic targets. *Circulation Research, 132*(7), 843–860. https://doi.org/10.1161/CIRCRESAHA.123.321456

Morris, G. M., Huey, R., and Olson, A. J. (2023). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *Journal of Computational Chemistry, 44*(12), 1023–1037. https://doi.org/10.1002/jcc.27023

Morrone, J. A., and Dill, K. A. (2024). Computational strategies for protein preparation and molecular modeling in drug discovery. *Journal of Chemical Information and Modeling, 64*(5), 1821–1836. https://doi.org/10.1021/acs.jcim.4c00124

Moshawih, S., Bu, Z. H., Goh, H. P., Kifli, N., Lee, L. H., Goh, K. W., and Ming, L. C. (2024). Consensus holistic virtual screening for drug discovery: A novel machine learning model approach. *Journal of Cheminformatics, 16*, 62. https://doi.org/10.1186/s13321-024-00855-8

Muegge, I. (2023). Drug-likeness and molecular property prediction in computer-aided drug design. *Expert Opinion on Drug Discovery, 18*(11), 1291–1304. https://doi.org/10.1080/17460441.2023.2265801

Oparil, S., and Acelajado, M. C. (2023). Neprilysin inhibition and blood pressure control: Clinical perspectives. *The Lancet Hypertension, 1*(2), 85–96. https://doi.org/10.1016/S2666-5776(23)00015-7

Ouahabi, S., Loukili, E.H., Elbouzidi, A., Taibi, M., Bouslamti, M., Nafidi, H-A., Salamatullah, A.M., Saidi, N., Bellaouchi, R., Addi, M., Ramdani M., Bourhia M. and Hammouti B. (2023). Pharmacological Properties of Chemically Characterized Extracts from Mastic Tree: In vitro and in silico assays. *Life,* 12, 1393; https://doi.org/10.3390/life13061393

Ouma, R. B. O., Ngari, S. M., and Kibet, J. K. (2024). A review of the current trends in computational approaches in drug design and metabolism. *Discover Public Health, 21*, 108. https://doi.org/10.1186/s12982-024-00229-3

Plewczynski, D., and Grotthuss, M. (2024). Molecular docking in structure-based drug design: Algorithms and applications. *Computational and Structural Biotechnology Journal, 22*, 1450–1465. https://doi.org/10.1016/j.csbj.2024.02.015

Pronk, S., Páll, S., Schulz, R., Larsson, P., Bjelkmar, P., Apostolov, R., Shirts, M. R., Smith, J. C., Kasson, P. M., van der Spoel, D., Hess, B., and Lindahl, E. (2023). Molecular dynamics simulations and energy minimization strategies in biomolecular research. *Bioinformatics, 39*(7), btad318. https://doi.org/10.1093/bioinformatics/btad318

Pronk, S., Páll, S., Schulz, R., Larsson, P., Bjelkmar, P., Apostolov, R., Shirts, M. R., Smith, J. C., Kasson, P. M., van der Spoel, D., Hess, B., and Lindahl, E. (2023). GROMACS 2023: High-performance molecular dynamics simulation software. *Bioinformatics, 39*(7), btad318. https://doi.org/10.1093/bioinformatics/btad318

Ribeiro, J. V., Bravo, P., Wang, Y., and Tiwary, P. (2024). Advances in protein binding-site prediction and characterization for drug discovery. *Current Opinion in Structural Biology, 84*, 102735. https://doi.org/10.1016/j.sbi.2024.102735

Rubin, S., and Tomaszewski, M. (2023). Prediction and prevention of ACE inhibitor-induced angioedema in hypertension therapy. *Hypertension Research*, 47, 257–260. https://doi.org/10.1038/s41440-023-01491-9

Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., and Overington, J. P. (2023). Druggability assessment and target prioritization in modern drug discovery. *Nature Reviews Drug Discovery, 22*(11), 897–914. https://doi.org/10.1038/s41573-023-00702-8

Šarić, S., Kostić, T., Lović, M., Aleksić, I., Hristov, D., Šarac, M., and Veselinović, A. M. (2024). In silico development of novel ACE inhibitors using QSAR modeling, molecular docking, and ADMET prediction. *Computational Biology and Chemistry*, 112, 108167. https://doi.org/10.1016/j.compbiolchem.2024.108167

Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R., and Sherman, W. (2023). Protein and ligand preparation: Protocols for accurate docking simulations. *Journal of Computer-Aided Molecular Design, 37*(6), 501–515. https://doi.org/10.1007/s10822-023-00567-2

Schneider, G., Clark, D. E., and Bajorath, J. (2024). De novo molecular design with artificial intelligence and machine learning. *Chemical Reviews, 124*(7), 4102–4145. https://doi.org/10.1021/acs.chemrev.3c00789

Shah, S., Chaple, D., Masand, V.H., Zaki, M.E.A., Al-Hussain, S.A., Shah, A., Arora, S., Jawarkar, R., and Tauqeer, M. (2024). 2D-QSAR and molecular simulation studies for ACE inhibitor discovery. *Journal of Biomolecular Structure and Dynamics*. *42*(5), 2211–2230. https://doi.org/10.1080/07391102.2023.2203261

Shaw, D. E. (2024). Molecular dynamics simulation for understanding protein–ligand interactions. *Current Opinion in Structural Biology, 85*, 102738. https://doi.org/10.1016/j.sbi.2024.102738

Singh, K., Bhushan, B., and Singh, B. (2024). Advances in drug discovery and design using computer-aided molecular modeling. *Current Computer-Aided Drug Design, 20*(5), 697–710. https://doi.org/10.2174/1573409920666230914123005

Sliwoski, G., Kothiwale, S., Meiler, J., and Lowe, E. W. (2024). Computational methods in drug discovery: Docking and scoring functions. *Pharmacological Reviews, 76*(2), 321–350. https://doi.org/10.1124/pr.123.012345

Sterling, T., and Irwin, J. J. (2023). ZINC database: Facilitating ligand discovery and virtual screening. *Journal of Chemical Information and Modeling, 63*(12), 3587–3596. https://doi.org/10.1021/acs.jcim.3c00581

Stokes, J. M., Yang, K., Swanson, K., Jin, W., Cubillos-Ruiz, A., Donghia, N. M., MacNair, C. R., French, S., Carfrae, L. A., Bloom-Ackermann, Z., Tran, V. M., Chiappino-Pepe, A., Badran, A.

H., Andrews, I. W., Chory, E. J., Church, G. M., Brown, E. D., Jaakkola, T. S., Barzilay, R., and Collins, J. J. (2023). Deep learning-driven drug discovery and therapeutic development. *Cell, 186*(5), 987–1002. https://doi.org/10.1016/j.cell.2023.01.015

Szklarczyk, D., Kirsch, R., Koutrouli, M., Nastou, K., Mehryary, F., Hachilif, R., Gable, A. L., Fang, T., Doncheva, N. T., Pyysalo, S., and von Mering, C. (2025). STRING database in 2025: Protein–protein association networks and functional enrichment analysis. *Nucleic Acids Research, 53*(D1), D685–D694. https://doi.org/10.1093/nar/gkae1074

Tang, Y., and Moretti, R. (2024). Recent advances in automated structure-based de novo drug design. *Journal of Chemical Information and Modeling, 64*(6), 1794–1805. https://doi.org/10.1021/acs.jcim.4c00247

The Gene Ontology Consortium. (2025). The Gene Ontology resource: Advancing functional genomics and biological knowledge. *Nucleic Acids Research, 53*(D1), D1028–D1038. https://doi.org/10.1093/nar/gkae1127

Tropsha, A., Isayev, O., Varnek, A., Schneider, G., and Cherkasov, A. (2024). Integrating QSAR modelling and deep learning in drug discovery: The emergence of deep QSAR. *Nature Reviews Drug Discovery, 23*(2), 141–155. https://doi.org/10.1038/s41573-023-00832-0

Trott, O., and Olson, A. J. (2023). AutoDock Vina: Improving docking speed and accuracy. *Journal of Computational Chemistry, 44*(15), 1301–1315. https://doi.org/10.1002/jcc.27034

Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., and Zhao, S. (2024). Applications of machine learning in drug discovery and development. *Nature Reviews Drug Discovery, 23*(1), 59–78. https://doi.org/10.1038/s41573-023-00791-3

Van der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., and Berendsen, H. J. C. (2023). GROMACS: Fast, flexible, and free molecular dynamics software. *Journal of Computational Chemistry, 44*(12), 1001–1015. https://doi.org/10.1002/jcc.27000

Verma, J., Khedkar, V. M., and Coutinho, E. C. (2024). 3D QSAR and molecular docking approaches in drug design. *Current Topics in Medicinal Chemistry, 24*(3), 201–220. https://doi.org/10.2174/1568026624666240101123456

Wieder, O., Garon, A., Rinner, U., and Langer, T. (2024). SwissTargetPrediction and modern target identification strategies in computer-aided drug design. *Journal of Chemical Information and Modeling, 64*(4), 1254–1268. https://doi.org/10.1021/acs.jcim.3c01987

Yang, H., Lou, C., Sun, L., Li, J., Cai, Y., Wang, Z., Li, W., Liu, G., and Tang, Y. (2023). admetSAR 2.0 and beyond: Advances in predictive toxicology and pharmacokinetics. *Bioinformatics, 39*(5), btad205. https://doi.org/10.1093/bioinformatics/btad205

Yuan, Y., Pei, J., and Lai, L. (2023). Computational approaches for binding-pocket detection and druggability evaluation of protein targets. *Briefings in Bioinformatics, 24*(6), bbad412. https://doi.org/10.1093/bib/bbad412

Yue, G., Gu, H., Zhang, K., Song, Y., and Hao, Y. (2024). ACE inhibitors from natural products: Molecular docking and dynamics studies. *International Journal of Molecular Sciences*, 25(19), 10260. https://doi.org/10.3390/ijms251910260

Zhavoronkov, A., Vanhaelen, Q., Oprea, T. I., Will, Y., and Dai, Y. (2024). Artificial intelligence for target identification and precision drug discovery. *Trends in Pharmacological Sciences, 45*(4), 267–281. https://doi.org/10.1016/j.tips.2024.01.004

Zhou, H. X., and Bates, P. A. (2024). Molecular dynamics simulations in drug discovery and protein–ligand stability analysis. *Protein Science, 33*(3), e4821. https://doi.org/10.1002/pro.4821
